Drug recall · September 27, 2023
Rasagiline Tablets 0.5mg recall
Why: Failed dissolution specifications - results obtained were below spec average.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Rasagiline Tablets 0.5mg, 30-count bottle, Rx only, Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A., NDC 0378-1270-93
- Lots / codes
Lot #: 3112444, Exp 8/2023
- Quantity
- 9,890 bottles
- Company
- Aurobindo Pharma USA Inc., East Windsor, NJ
- Distribution
- USA nationwide
- Initiated
- August 2, 2023 · Voluntary: Firm initiated
- Classified
- September 18, 2023
- Reported
- September 27, 2023
- Ended
- August 19, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Rasagiline
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.